October 29, 2013
U.S. Federal track and trace regulations embodied in H.R. 3204, the Drug Quality and Security Act, and its implications for companies along the supply chain were the subject of a just published article by Trisha Gladd, editor of Pharmaceutical Online.
In interviews for the article, TraceLink discussed the segment-specific regulatory requirements of H.R. 3204 and shared insights into issues that pharmaceutical companies and their trading partners have started to consider as they begin initial planning for this expected-to-pass bill.
To read the entire article, follow this link: H.R. 3204 Could Emerge From The Serialization "Thunderdome" This Month – Then What?